When you go in for a dental appointment, you reasonably expect that you will receive attentive, high-quality treatment. Unfortunately, that is not always the case. Dental negligence is a serious problem in the United States. In fact, according to data published by the National Practitioner Data Bank (NPDB), approximately one in every seven medical malpractice…

The short answer is yes.  The truth is any licensed dentist in North Carolina is permitted to place dental implants.  A more appropriate title to the article is “Should A General Dentist Place Dental Implants?”  The answer to that question is maybe.  An unqualified general dentist who places dental implants may be liable for dental…

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death. Recalled Product(s): AirLife Resuscitation Devices Product Codes: 2K8004, 2K8035C2, 2K8017, 2K8005, 2K8018, 2K8008, 2K8036, 2K8001, RE1DK5445D,2K8035M,2K8039,2K8004C2 Manufacturing Dates: February 5, 2018 to February 28, 2018 Distribution Dates: February 2,…

ISSUE: Haemonetics recently received reports of low pH readings for platelets stored in the CLX HP bag in certain lots of the Acrodose PLus and PL systems. In some instances the drop in pH is accompanied by a yellow discoloration of the storage bag. Platelets with pH lower than 6.2 and a lack of “swirl”…

ISSUE: FDA is alerting health care professionals to a voluntary recall of all non-expired products marketed as sterile made by Coastal Meds due to visible particles in some of the drug vials for injection. BACKGROUND: During FDA’s recent inspection of Coastal Meds, investigators observed visible particulates and poor sterile production practices which further raise concerns…

FDA is advising caution before prescribing the antibiotic clarithromycin (Biaxin) to patients with heart disease because of a potential increased risk of heart problems or death that can occur years later. FDAs recommendation is based on a review of the results of a 10-year follow-up study of patients with coronary heart disease from a large clinical trial that first observed this safety issue.

ISSUE: Hospira is voluntarily recalling 3 lots of Labetalol Hydrochloride Injection, USP, 100 mg/20 mL Vial (NDC 0409-2267-20), and one lot of Labetalol Hydrochloride Injection, USP, Novaplus (NDC 0409-2267-25) to the hospital/institution level. Hospira, Inc. initiated this recall due to the discovery of cracks on the rim surface of vials for these lots, which is…